Speaker Profile

	Name
	Jinhyuk Chung, Ph. D.
	Title
	Chief Executive Officer/ Chief Research Officer
	inotitute
	Field of Study Dr. Jinhyuk Chung received his chemistry degree from Renselaer Polytechnic Institute, Troy NY, in 2004 for his leading dissertation research that dealt with the cause and the treatment strategies for amyotrophic lateral sclerosis. After a brief post-doctoral training from his doctoral advisor, Prof. Wilfredo Colon, Dr. Chung returned to South Korea to pursue nanomedicinal
Contact Details	research.
Organization Name: NanoMedicine Research Co.	His current research interest is in developing a novel anti-cancer therapeutic agent named OFeCa-1, a pH- sensitive organo-metalic nanoparticle moiety. Borrowing
Address: Sanhakyeon Bldg 705 Choongnam Natl' Univ. Daejon, South Korea	induced cell deaths, Dr. Chung aims to treat difficult cancers such as lung and brain tumors using only the benign biological metals such as calcium and iron.
Phone: Office 82-2-587-1333 Cell 82-010-5091-2844 Fax: 82-2-587-1335 Email: j.f.chung@nmrpharma.com Website: www.nmrpharma.com	 Past Experience Chief Executive Officer / Chief Research Officer (NanoMedicine Research Co., March, 2006 ~ Current) Post Doctoral Research Associate (RPI, Jan 2005 ~ Aug 15, 2005) Ph. D. in Chemistry (RPI, Aug 2002 ~ Dec 2004). B.A. in Biophysics and Biochemistry (RPI, Aug 2000 ~ Dec. 2003) KAIST (Fall 1999~ Spring 2000) Works PCT/KR2007/001313 "Water-soluble organometallic na noparticles and method for preparing the same" Jinhyuk Chung and Soonhai Hong, March, 2007 NanoMedicine Research Co. Founded, April 2006. U.S. Provisional Patent No. 60/543,786 "Compositions a nd Methods for Treating Amyotrophic Lateral Sclerosis (ALS)" Chung J. et al., Feb. 2005 "Cu/Zn superoxide dismutase can form pore-like structur es." Chung J. et al., Biochem Biophys Res Commun. 20 03 Dec 26; 312(4): 873-6

· · · · · · · · · · · · · · · · · · ·	
1	
1	
1	